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Increased frequency of CD4+CD57+ 
senescent t cells in patients with 
newly diagnosed acute heart 
failure: exploring new pathogenic 
mechanisms with clinical relevance
Jong-chan Youn  1,2, Min Kyung Jung2, Hee Tae Yu2,3, Ji-Soo Kwon4, Jeong-Eun Kwak  4,  
Su-Hyung Park  4,5, In-Cheol Kim6, Myung-Soo Park7, Sun Ki Lee7, Suk-Won choi7, 
Seongwoo Han7, Kyu-Hyung Ryu7, Seok-Min Kang  3 & eui-cheol Shin  2,4
Recent animal studies showed t cells have a direct pathogenic role in the development of heart 
failure (HF). However, which subsets of T cells contribute to human HF pathogenesis and progression 
remains unclear. We characterized immunologic properties of various subsets of T cells and their clinical 
implications in human HF. Thirty-eight consecutive patients with newly diagnosed acute HF (21 males, 
mean age 66 ± 16 years) and 38 healthy control subjects (21 males, mean age 62 ± 12 years) were 
enrolled. We found that pro-inflammatory mediators, including CRP, IL-6 and IP-10 and the frequencies 
of CD57+ T cells in the CD4+ T cell population were significantly elevated in patients with acute HF 
compared to control subjects. A functional analysis of T cells from patients with acute HF revealed that 
the CD4+CD57+ T cell population exhibited a higher frequency of IFN-γ- and tnf-α- producing cells 
compared to the CD4+CD57− T cell population. Furthermore, the frequency of CD4+CD57+ t cells at 
baseline and its elevation at the six-month follow-up were significantly related with the development 
of cardiovascular (CV) events, which were defined as CV mortality, cardiac transplantation, or 
rehospitalization due to HF exacerbation. In conclusion, CD4+CD57+ senescent t cells showed more 
inflammatory features and polyfunctionality and were associated with clinical outcome in patients with 
acute HF. More detailed study for senescent T cells might offer new opportunities for the prevention and 
treatment of human HF.
Heart failure (HF) is an important cardiovascular syndrome with significant morbidity and high mortality 
rates. The increasing prevalence of HF has contributed to rapidly expanding health care costs1,2. Since the early 
1990’s, inflammation and immunological responses have been recognized as clinically relevant features of HF3. 
Numerous studies have reported that circulating levels of tumour necrosis factor-α (TNF-α) were correlated with 
HF severity and prognosis. Based on those observations, large-scale clinical trials were launched that targeted 
1Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The 
Catholic University of Korea, Seoul, Republic of Korea. 2Laboratory of Immunology and Infectious Diseases, 
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 
Daejeon, Republic of Korea. 3Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College 
of Medicine, Seoul, Republic of Korea. 4BioMedical Science and Engineering Interdisciplinary Program, Korea 
Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. 5Laboratory of Translational 
Immunology and Vaccinology, Graduate School of Medical Science and Engineering, Korea Advanced Institute of 
Science and Technology (KAIST), Daejeon, Republic of Korea. 6Division of Cardiology, Keimyung University Dongsan 
Medical Center, Daegu, Republic of Korea. 7Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University 
College of Medicine, Hwaseong, Republic of Korea. Jong-Chan Youn and Min Kyung Jung contributed equally. 
Correspondence and requests for materials should be addressed to J.-C.Y. (email: jong.chan.youn@gmail.com) or 
S.-M.K. (email: smkang@yuhs.ac) or E.-C.S. (email: ecshin@kaist.ac.kr)
Received: 6 September 2018
Accepted: 20 August 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:12887  | https://doi.org/10.1038/s41598-019-49332-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
TNF-α with infliximab or etanercept4,5. Those trials were deemed unsuccessful, and they were terminated pre-
maturely, due to the lack of clinical benefit, and in some patients, disease progression4,5. Although TNF-α block-
ers failed in trials, studies continue to investigate more sophisticated and specific immunological aspects of HF 
pathogenesis2.
Recently, the pathologic role of T cells in the development of HF was demonstrated in two mouse models; 
one was a non-ischaemic, pressure-overload HF model6,7 and the other was an ischaemic HF model8. These stud-
ies showed that T cells have a direct pathogenic role in the development of HF, not just as an epiphenomenon. 
However, which subsets of T cells contribute to HF pathogenesis and progression remains unclear. Therefore, we 
designed our clinical study to evaluate which subset of T cells has pathological immune characteristics and what 
their clinical implication is in patients with acute HF.
Memory T cells undergo replicative senescence via repetitive proliferation by antigen stimulation. Senescent 
T cells have the ability to produce large quantities of pro-inflammatory cytokines and cytotoxic mediators and 
have been implicated in the pathogenesis of many chronic inflammatory diseases, including cardiovascular dis-
eases9–11. In humans, senescent T cells typically lose expression of CD28 and acquire the expression of CD57 with 
repetitive replication. Therefore the frequency of CD28null and CD57+ T cells in the peripheral blood increases 
with age9–11. A growing body of evidence suggests that senescent T cells also have pathogenic potential in cardio-
vascular diseases, such as hypertension, atherosclerosis, and myocardial infarction, underscoring the detrimental 
roles of these cells in various chronic inflammatory responses. We previously found that CD8+CD57+ T cells 
were associated with the development of hypertension and the progression of myocardial infarction12–14. Though 
which subsets of T cells contribute to deleterious inflammation in HF progression is unclear, we hypothesized 
that senescent T cells may be involved in the progression of HF, as hypertension, myocardial infarction, and HF 
are all tied to the aging process.
In the present study, we focused on CD28null and CD57+ replicative senescent T cells isolated from patients 
with acute HF. We examined immunological characteristics and clinical implication of various subsets of T cells, 
particularly CD4+CD57+ senescent T cells. We found that patients with acute HF had elevated frequencies of 
CD4+CD57+ senescent T cells, and this increase was associated with clinical outcome.
Materials and Methods
Study population. The present study prospectively enrolled 38 newly diagnosed consecutive patients with 
acute HF (12 ischemic, 26 non-ischemic) at the Severance Cardiovascular Hospital, from October 2014 to August 
2015. Patients were eligible for the study when they displayed rapid onset of signs or symptoms of HF and one 
of the following criteria: (i) lung congestion or (ii) objective findings of left ventricular systolic dysfunction or 
structural heart disease. Lung congestion was defined as ‘congestion’ on a chest X-ray or rales in a physical exam-
ination. Patients that had recovered from acute HF and were ambulatory during hospitalization were eligible 
for the study. Patients were excluded from the study when they had a history of overt chronic inflammatory 
diseases, such as rheumatoid arthritis or autoimmune disease, and/or were taking anti-inflammatory medica-
tions. The primary endpoint included a cardiovascular (CV) event, defined as the composite of death, urgent 
cardiac transplantation, or rehospitalization due to worsening heart failure. In the Yonsei Cardiovascular Genome 
Centre, we enrolled 38 age- and sex-matched healthy control subjects that had no history of HF. These controls 
were evaluated with routine physical examinations, laboratory tests, and radiological examinations. The base-
line characteristics of the acute HF and control groups are summarized in Table 1. This study was carried out in 
accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review 
board (IRB) of Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea (IRB number 
4-2012-0027), and written informed consent was obtained from all of the participants15.
Measurement of pro-inflammatory mediators. We sampled peripheral blood after patients achieved 
clinical stabilization, according to current HF guidelines15,16. Clinical stabilization was defined as readiness for 
discharge from the hospital: congestion was absent, and a stable, oral diuretic regimen was established for at 
least 48 h15. We collected blood samples at a relatively consistent time point, that is, on the day of or before dis-
charge15. The concentration of C-reactive protein (CRP) was measured with an enzyme-linked immunosorbent 
assay (R&D system, Minneapolis, MN). We performed flow cytometry with the BD cytometric bead array kit (BD 
Biosciences, San Jose, CA) to measure other pro-inflammatory mediators, including interleukin-6 (IL-6), TNF-α, 
monokine-induced by gamma interferon (MIG), interferon gamma-induced protein 10 (IP-10), and macrophage 
inflammatory protein 1α (MIP1α). Samples were processed according to the manufacturer’s instructions. Mixed 
capture beads (50 μl) and each serum sample (50 μl) were incubated for 1 h at room temperature (RT), and then 
mixed phycoerythrin detection reagents (50 μl) were added to the bead-sample mixture and incubated for 2 h at 
RT15. The samples were washed and assessed with an LSR II Flow Cytometer (BD Biosciences) and then the data 
were analysed with FlowJo software, version 9.2 for Mac (TreeStar, Ashland, OR)15.
Immunophenotyping analysis of peripheral blood mononuclear cells. Peripheral blood mon-
onuclear cells (PBMCs) were separated from whole blood using Ficoll-Hypaque (GE Healthcare, Uppsala, 
Sweden), and then, cryopreserved until use15. Cryopreserved PBMCs were thawed and analysed with flow 
cytometry. Briefly, cells were stained with fluorochrome-conjugated monoclonal antibodies against surface anti-
gens for 20 min at 4 °C. The antibodies were anti-CD3-Horizon V500, anti-CD4-PE-Cy7, anti-CD8-APC-H7, 
anti-CD28-APC (all from BD Biosciences) and anti-CD57-Pacific blue (Biolegend, San Diego, CA). Multicolour 
flow cytometry was performed with an LSR II Flow Cytometer, and data was analysed with FlowJo software.
In vitro stimulation of T cells and intracellular cytokine staining. PBMCs were stimulated with 
anti-CD3 antibody (100 ng/ml) for 6 h. Then, after 1 h of incubation, brefeldin A (GolgiPlug, BD Biosciences) 
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and monensin (GolgiStop, BD Biosciences) were added to the culture to cause intracellular cytokine accu-
mulation. Cells were surface-stained with anti-CD3-Horizon V500, anti-CD4-PE-Cy7, anti-CD8-APC-H7, 
anti-CD28-APC, and anti-CD57-Pacific blue. Then, cells were fixed and permeabilized with the Fixation/
Permeabilization Buffer Kit (BD Biosciences). Cells were then stained to detect intracellular cytokines with 
anti-TNF-PE-Cy7 and anti-IFN-γ-FITC (all from BD Biosciences). FACS analysis was performed with an LSR II 
Flow Cytometer, and data were analysed with FlowJo software.
Statistical analysis. Continuous variables are reported as the mean ± SD. Categorical variables are 
expressed as percentages of the group totals. Continuous variables were compared with independent t-tests, and 
discrete variables were compared with the chi-squared method. Intra-group comparisons were performed with 
the paired t-test, and the Wilcoxon signed-rank test was used to verify the results. The Kaplan-Meier method 
was used to assess the cumulative incidence of CV events. For cumulative CV events, the baseline frequency of 
CD4+CD57+ T cells was defined with a cut-off point of 3.65, according to Youden index (sensitivity 66.7% and 
specificity 68.4%). The statistical significance of the curves was calculated with the log-rank test. Statistical anal-
yses were performed with SPSS 13.0. (SPSS Inc., Chicago, IL).
Results
Clinical, laboratory, and senescent T-cell characteristics of patients with acute HF. We com-
pared the clinical characteristics, laboratory findings, and senescent T-cell frequencies between patients with 
newly diagnosed acute HF and age-and sex-matched control subjects (Table 1). Acute HF patients showed sig-
nificantly increased white blood cell count (×103/μl) (8.71 ± 3.86 vs. 5.94 ± 1.58, p < 0.001), blood urea nitrogen 
(mg/dl) (23.9 ± 12.5 vs. 18.2 ± 5.1, p = 0.014) and significantly decreased albumin (mg/dl) (3.7 ± 0.4 vs. 4.5 ± 0.3, 
p < 0.001). However, there was no significant difference in body mass index, haemoglobin and total cholesterol 
level.
Pro-inflammatory mediators and CD4+ senescent t-cell fractions are increased in patients with 
newly diagnosed acute HF. First, we compared serum levels of pro-inflammatory mediators between 38 
patients with acute HF and 38 age- and sex-matched control subjects. Patients with acute HF showed significantly 
elevated levels of CRP, IL-6 and IP-10 compared to healthy controls. Serum levels of TNF-α, MIG and MIP-1α 
were not significantly different between groups (Fig. 1).
Next, we compared the frequencies of CD28null and CD57+ senescent T cells in the PBMC populations 
between patients with acute HF and control subjects. We found that the frequencies of CD28null and CD57+ T cells 
in the CD4+ T cell population were significantly elevated in patients with acute HF compared to control subjects 
Acute HF (n = 38) Control (n = 38) p-Value
Age (y) 66 ± 16 62 ± 12 0.208
Male: Female (N, %) 21:17 (55.3%:44.7%) 21:17 (55.3%:44.7%) —
BMI (kg/m2) 23.8 ± 4.2 24.8 ± 4.3 0.082
WBC (×103/μl) 8.71 ± 3.86 5.94 ± 1.58 <0.001*
Haemoglobin (g/dl) 13.7 ± 2.3 13.9 ± 1.3 0.604
BUN (mg/dl) 23.9 ± 12.5 18.2 ± 5.1 0.014*
Creatinine (mg/dl) 1.16 ± 0.55 1.03 ± 0.17 0.176
Total cholesterol (mg/dl) 154.9 ± 59.1 178.2 ± 46.1 0.069
Albumin (mg/dl) 3.7 ± 0.4 4.5 ± 0.3 <0.001*
CRP (mg/l) 6.11 ± 6.80 1.97 ± 3.14 0.001*
IL-6 (pg/ml) 7.30 ± 10.17 1.43 ± 1.98 0.001*
TNF-α (pg/ml) 7.39 ± 10.17 3.45 ± 6.30 0.272
MIG (pg/ml) 362.8 ± 774.2 115.6 ± 221.0 0.066
IP-10 (pg/ml) 248.1 ± 169.2 101.2 ± 58.6 <0.001*
MIP-1α (pg/ml) 28.9 ± 58.7 23.5 ± 25.7 0.610
CD4+CD28null T cell fraction in 
CD4+ T cell population (%) 2.8 ± 3.6 1.4 ± 1.2 0.035
*
CD4+CD57+ T cell fraction in 
CD4+ T cell population (%) 5.0 ± 3.9 2.5 ± 1.5 0.001
*
CD8+CD28null T cell fraction in 
CD8+ T cell population (%) 38.3 ± 17.5 32.7 ± 12.1 0.118
CD8+CD57+ T cell fraction in 
CD8+ T cell population (%) 34.8 ± 14.7 31.8 ± 12.0 0.338
Table 1. Clinical characteristics, laboratory findings, and senescent T cell subsets for patients with newly 
diagnosed acute HF and age- and sex-matched control subjects. Values represent the number (%) of patients 
or the mean ± standard deviation, as indicated. *p-values < 0.05 were considered significant. HF, heart failure; 
BMI, body mass index; WBC, white blood cell count; BUN, blood urea nitrogen; CRP, C-reactive protein; 
IL-6, interleukin-6; TNF-α, tumour necrosis factor-α; MIG, monokine-induced by gamma interferon; IP-10, 
interferon gamma-induced protein 10; MIP-1α, macrophage inflammatory protein-1α.
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(CD4+CD28null T cell fraction: 2.8 ± 3.6% vs. 1.4 ± 1.2%, p = 0.035; CD4+CD57+ T cell fraction: 5.0 ± 3.9% vs. 
2.5 ± 1.5%, p = 0.001; Fig. 2a,b). In fact, the CD28null and CD57+ T cell subpopulations showed considerable 
overlap (Fig. 2c). Conversely, the frequencies of CD28null and CD57+ T cells in the CD8+ T cell population were 
not significantly different between the HF and control groups (CD8+CD28null T cell fraction: 38.3 ± 17.5% vs. 
32.7 ± 12.1%, p = 0.118; CD8+CD57+ T cell fraction: 34.8 ± 14.7% vs. 31.8 ± 12.0%, p = 0.338; Fig. 2d,e).
We analysed the functional characteristics of CD4+CD57+ T cells compared to the characteristics of 
CD4+CD57− T cells from patients with acute HF. We treated cells with an anti-CD3 antibody to mimic T-cell 
receptor (TCR) stimulation. Subsequent intracellular cytokine staining for IFN-γ and TNF-α showed that the 
frequencies of IFN-γ- and TNF-α- producing cells in the CD4+CD57+ T cell population were significantly higher 
than those in the CD4+CD57− T cell population (p < 0.001, Fig. 3a). In addition, the frequency of T cells that pro-
duced both IFN-γ and TNF-α was also significantly higher in the CD4+CD57+ T cell population compared to the 
CD4+CD57− T cell population (p < 0.001, Fig. 3a). A gating strategy for flow cytometry analysis is presented in 
Fig. 3b. Similar results were obtained with CD4+CD28null T cells. The CD4+CD28null T cell population had higher 
frequencies of IFN-γ+ and TNFα+ cells than the CD4+CD28+ T cell population (p < 0.01, Fig. 3c). We also com-
pared the frequencies of IFN-γ+ and TNF-α+ cells among CD4+CD57+ and CD4+CD57− T cells from healthy 
individuals and found that the CD4+CD57+ T cell population has higher frequencies of IFN-γ+ and TNF-α+ cells 
than the CD4+CD57− T cell population, even in healthy individuals (p < 0.001, Fig. 3d). However, the frequency 
of IFN-γ+ cells among CD4+CD57+ T cells was significantly higher in patients with acute HF than in healthy 
individuals (p < 0.05, Fig. 3e). A similar result was found for the frequency of TNF-α+ cells among CD4+CD57+ 
T cells although it did not reach statistical significance (p = 0.052, Fig. 3e).
The frequencies of CD4+CD57+ T cells at baseline and at the 6-month follow-up were related 
to clinical outcome in patients with acute HF. We evaluated whether the elevated frequency of 
CD4+CD57+ T cells observed at baseline was associated with the clinical outcome in patients with acute HF. 
During a median follow-up period of 640 (range: 6–947) days, we observed 2 (5.3%) cardiovascular-related 
Figure 1. Pro-inflammatory mediators are elevated in patients with acute HF. Serum samples were obtained 
from healthy controls and patients with acute HF. (a) Enzyme-linked immunosorbent assay results show CRP 
concentrations. (b–f) Cytometric bead array results show (b) IL-6, (c) TNF-α, (d) MIG, (e) IP-10, and (f) 
MIP-1α concentrations. Medians and standard deviations are presented for each group. N.S., non-significant.
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deaths, 2 (5.3%) urgent heart transplantations, and 12 (31.6%) rehospitalizations due to HF exacerbation. The 
clinical, echocardiographic, laboratory, and senescent T-cell characteristics of the 38 patients with acute HF were 
compared between patients that did and those that did not experience a CV event (Table 2). Patients that experi-
enced CV events were more likely to have diabetes and showed significantly reduced renal function compared to 
patients with no CV events. Although these groups exhibited similar pro-inflammatory mediator levels, patients 
with CV events showed significantly higher frequencies of CD4+CD28null and CD4+CD57+ T cells at baseline 
than patients without CV events (CD4+CD28null T cells: 4.5 ± 4.6% vs. 1.5 ± 1.7, p = 0.027; CD4+CD57+ T cells: 
6.9 ± 4.9% vs. 3.5 ± 1.9%, p = 0.019; Fig. 4a). We then divided acute HF patients into two groups according to 
the baseline CD4+CD57+ T cell frequency, based on the Youden index. The cumulative Kaplan-Meier estimates 
of CV events revealed that patients with high baseline CD4+CD57+ T cell fractions showed significantly worse 
clinical outcomes than patients with low baseline CD4+CD57+ T cell fractions (p=0.020; Fig. 4b).
Figure 2. The frequencies of CD4+CD28null and CD4+CD57+ T cells are elevated in patients with acute HF. 
(a,b) The percentages of (a) CD4+CD28null T cells, (b) CD4+CD57+ T cells in the CD4+ T cell populations 
were determined in PBMCs from healthy controls and patients with acute HF. (c) A gating strategy for flow 
cytometry analysis is presented. (d,e) The percentages of (d) CD8+CD28null T cells, and (e) CD8+CD57+ T cells 
in the CD8+ T cell populations were determined in PBMCs from healthy controls and patients with acute HF. 
Medians and standard deviations are presented for each group. N.S., non-significant.
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Figure 3. The CD4+CD57+ T cell population exhibits higher frequencies of IFN-γ- and TNF-α-producing cells 
than the CD4+CD57− T cell population. PBMCs were stimulated with anti-CD3 antibody, and intracellular 
cytokine staining was performed to detect IFN-γ and TNF-α. (a) The frequencies of IFN-γ+, TNF-α+, and 
double positive (IFN-γ+TNF-α+) cells are shown for CD4+CD57+ T-cell and CD4+CD57− T-cell populations 
from patients with acute HF. (b) A gating strategy for flow cytometry analysis is presented. (c) The frequencies 
of IFN-γ+, TNF-α+, and double positive (IFN-γ+TNF-α+) cells are shown for CD4+CD28+ T-cell and 
CD4+CD28null T-cell populations from patients with acute HF. (d) The frequencies of IFN-γ+ and TNF-α+ 
cells are shown for CD4+CD57+ T-cell and CD4+CD57− T-cell populations from healthy individuals. (e) The 
frequencies of IFN-γ+ and TNF-α + cells among the CD4+CD57+ T-cell population were compared between 
healthy individuals and patients with acute HF.
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Finally, we examined the frequency of CD4+CD57+ T cells at the 6-month follow-up in 16 patients with avail-
able PBMCs. We found that patients with CV events showed significant elevations in CD4+CD57+ T cell frequen-
cies at the 6-month follow-up compared to baseline frequencies (17.10 ± 14.75% vs. 8.70 ± 6.14%, p = 0.044). In 
contrast, patients without CV event showed no significant change in CD4+CD57+ T cell frequency over time 
(4.31 ± 3.01% vs. 3.30 ± 1.35%, p = 0.158; Fig. 4c). Regarding the association of gender and diabetic status with 
CD4+CD57+ T cell frequencies at baseline and at the six-month follow-up, there was no significant differences 
CV event
(N = 16, 42.1%)
No CV event
(N = 22, 57.9%) P-value
Age (y) 67 ± 16 65 ± 16 0.658
Male: Female (N, %) 10:6 (62.5%:37.5%) 12:10 (54.5%:45.5%) 0.439
Ischaemic aetiology (N, %) 6 (37.5%) 6 (27.3%) 0.374
Hypertension (N, %) 10 (62.5%) 15 (68.2%) 0.490
Diabetes (N, %) 9 (56.3%) 5 (22.7%) 0.047*
Weight (kg) 64.6 ± 10.2 61.5 ± 15.0 0.476
BMI (kg/m2) 22.7 ± 2.9 24.7 ± 3.8 0.452
Echocardiographic parameters
LVEF (%) 26.9 ± 13.3 28.1 ± 10.2 0.742
LVEDD (mm) 65.0 ± 9.4 61.4 ± 10.7 0.310
LVESD (mm) 56.6 ± 11.5 52.8 ± 11.1 0.334
LAVI (ml/m2) 63.1 ± 27.2 57.6 ± 19.7 0.490
E/E’ 27.8 ± 14.2 19.8 ± 10.0 0.076
Laboratory parameters
WBC (×103/μl) 8.98 ± 2.55 8.52 ± 4.64 0.599
Haemoglobin (g/dl) 12.8 ± 2.5 14.3 ± 1.9 0.060
Sodium (mmol/l) 137.2 ± 3.9 140.5 ± 8.2 0.143
Total cholesterol (mg/dl) 164.5 ± 83.2 147.9 ± 32.9 0.399
Albumin (g/dl) 3.7 ± 0.4 3.8 ± 0.4 0.756
eGFR (ml/min/1.73 m2) 58.7 ± 24.4 73.4 ± 16.4 0.046*
NT-proBNP (pg/ml) 8044 ± 10256 8595 ± 10036 0.869
Pro-inflammatory mediators
CRP (mg/l) 8.27 ± 7.30 4.54 ± 6.11 0.096
IL-6 (pg/ml) 8.63 ± 8.57 6.33 ± 11.29 0.499
TNF-α (pg/ml) 4.98 ± 12.3 9.14 ± 25.4 0.549
MIG (pg/ml) 564.5 ± 1108.7 216.1 ± 352.9 0.241
IP-10 (pg/ml) 228.3 ± 142.0 262.4 ± 188.4 0.547
MIP-1α (pg/ml) 27.8 ± 41.6 29.7 ± 69.5 0.923
Medications at discharge
RAS blockers (N, %) 12 (75.0%) 17 (77.3%) 0.584
Beta-blockers (N, %) 6 (37.5%) 15 (68.2%) 0.099
Aldosterone antagonist (N, %) 11 (68.8%) 17 (77.3%) 0.713
Digoxin (N, %) 3 (18.8%) 10 (45.5%) 0.165
Senescent T cell subsets
CD4+CD28null T cell fraction in 
CD4+ T cell population (%) 4.5 ± 4.6 1.5 ± 1.7 0.027
*
CD4+CD57+ T cell fraction in 
CD4+ T cell population (%) 6.9 ± 4.9 3.5 ± 1.9 0.019
*
CD8+CD28null T cell fraction in 
CD8+ T cell population (%) 43.2 ± 18.8 34.5 ± 15.9 0.134
CD8+CD57+ T cell fraction in 
CD8+ T cell population (%) 38.7 ± 16.1 31.9 ± 13.1 0.165
Table 2. Clinical, echocardiographic, laboratory, and senescent T-cell characteristics in patients with acute 
HF that experienced or did not experience a CV event. Values represent the number (%) or the mean ± 
standard deviation, as indicated. *p-values < 0.05 are considered significant. CV, cardiovascular; BMI, body 
mass index; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, 
left ventricular end-systolic dimension; LAVI, left atrial LAVI, left atrial volume index volume index; WBC, 
white blood cell; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal of the prohormone brain 
natriuretic peptide; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumour necrosis factor-α; MIG, 
monokine-induced by gamma interferon; IP-10, interferon gamma-induced protein 10; MIP-1α, macrophage 
inflammatory protein-1α; RAS, renin angiotensin aldosterone system. Discrete variables were compared with 
the chi-squared method; continuous variables were compared with independent Student’s t-tests.
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between male and female patients and between diabetic and non-diabetic patients, as shown in Supplementary 
Fig. 1.
Discussion
Pathologic roles of CD4+ T cells in the development of HF have been well documented in recent animal stud-
ies6–8. In murine models of non-ischaemic, pressure-overload HF, activated CD4+ T cells were shown to infiltrate 
the myocardium and play a crucial role in promoting cardiac fibrosis, hypertrophy, and remodelling through 
cytokine release6,7. In a chronic ischaemic HF mouse model, the CD4+ T cell population was also expanded and 
activated. Moreover, studies in ischaemic HF models have shown that cardiac and splenic T cells were primed 
to induce cardiac injury and remodelling, and they retained this capability after an adoptive transfer8. Recently, 
Ramos et al. reported that the myocardial and immunological aging processes were intertwined phenomena, and 
that CD4+ T cells mediated cardiac inflammation and functional impairment in aged mice, even in the absence 
of clear tissue damage or concomitant infection17.
Previously, it was unclear which subsets of CD4+ T cells contributed to HF progression. In the present study, 
we demonstrated that CD4+CD57+ senescent T cells were elevated in patients with acute HF, and this elevation 
was associated with clinical outcome. Moreover, patients with acute HF had elevated levels of pro-inflammatory 
mediators, such as CRP, IL-6 and IP-10. A functional analysis of T cells from patients with acute HF revealed that 
the CD4+CD57+ T cell population exhibited a higher frequency of IFN-γ- and TNF-α- producing cells compared 
to the CD4+CD57− T cell population. Furthermore, the frequency of CD4+CD57+ T cells at baseline and its 
elevation at the 6-month follow-up were significantly related to clinical outcome in patients with acute HF. All 
Figure 4. The frequencies of CD4+CD57+ T cells at baseline and at the 6-month follow-up are related to clinical 
outcome in patients with acute HF. (a) Baseline frequencies of CD4+CD57+ T cells in PBMCs from patients 
with acute HF were compared between those without and those with CV events. Medians are presented for each 
group. (b) Cumulative Kaplan-Meier estimates of CV events in patients with acute HF are compared between 
patients with different baseline CD4+CD57+ T cell frequencies (according to the Youden index). (c) Baseline 
and 6-month CD4+CD57+ T cell frequencies in PBMCs from patients with acute HF are compared between 
those without and those with CV events. N.S., non-significant.
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patients were treated with guideline-directed medical therapy during the follow-up period. Increased frequencies 
of CD4+CD57+ T cells in patients with a CV event may be caused by HF progression, considering the unchanged 
frequencies of CD4+CD57+ T cells in patients without CV events.
The clinical relevance of senescent CD4+ T cells in patients with chronic HF has been reported previously. 
Senescent CD4+ T cells were associated with chronic HF severity, and their frequency was an independent pre-
dictor of mortality18. In addition, senescent T cells were elevated in patients with an advanced clinical status of 
chronic HF, which suggested that they might contribute to disease progression19.
‘Immune aging’ or ‘immunosenescence’ can be briefly described by restriction of diversity, 
hypo-responsiveness to proper antigens, and enhanced non-specific pro-inflammatory responses20. A growing 
body of evidence has suggested that, in addition to HF, senescent T cells are involved in the pathogenesis of 
several cardiovascular diseases, including acute coronary syndrome21–23, myocardial infarction13,24, and hyper-
tension12,25,26. Recently, we reported that CD8+CD57+ T-cell frequency was significantly higher in patients with 
pre-diabetes and type 2 diabetes compared to subjects with normal glucose tolerance, though CD4+CD57+ T-cell 
frequency was not27. In addition, we showed that the frequency of CD8+CD57+ T cells is an independent predic-
tor of hyperglycaemia development27. The role of senescent T cells in the development hyperglycaemia and the 
progression of heart failure may be linked and partly explain the poor clinical outcome of diabetic HF patients.
Although inflammation is a major component of HF, clinical trials have shown that blocking TNF-α was not 
successful in controlling HF4,5. This failure might be attributable to the contributions of multiple mediators in 
the pathogenesis and progression of HF. Consequently, blocking the action of a single cytokine (e.g., TNF-α) 
might not be enough to control all the pathological immune responses involved in HF. Therefore, to identify 
more suitable targets for HF treatments, we must better characterize the immunological mechanisms involved in 
HF pathophysiology28. Currently, investigations in HF animal models are testing anti-inflammatory therapeutics 
with novel targets, including chemokine (C–C motif) receptor 229, intercellular adhesion molecule 130, and T-cell 
co-stimulators31. The results of the present study suggested that detailed studies on CD4+CD57+ senescent T cells 
in the context of HF might promote the development of novel anti-inflammatory therapeutics for HF treatment32.
The present study had several limitations. First, the study design was observational, rather than interven-
tional. Thus, identifying a direct cause-and-effect relationship would be difficult. Relatively high baseline levels 
of pro-inflammatory mediators in control subject is another limitation of the observational study. Even though 
we enrolled age- and sex-matched control subjects who had no history of HF, the mean age of the control group 
was sixty-two and some of them had co-morbidities of hypertension and dyslipidemia which were well con-
trolled. Old age and comorbidities might contribute to the increased level of pro-inflammatory mediators in these 
control subjects. Second, results from our study population are not generalizable to patients with compensated 
stable HF or patients with chronic HF that experience an acute exacerbation. Rather, our results pertained to 
treatment-naive patients with newly diagnosed acute HF. Third, T-cell changes at the 6-month follow-up could 
only be analysed in a small population, due to the limited availability of PBMCs. Fourth, the difference in clinical 
severity of HF may have affected the baseline leve of CD4+CD57+ T cells. However, we enrolled acute HF patients 
who recovered from the initial decompensation and were ready for discharge. Very sick patients who died in the 
index admission period were excluded from this study. Moreover, we sampled peripheral blood to measure medi-
ators of inflammation and T-cell immunological characterization after patients achieved clinical stabilization 
according to current medical guidelines. Clinical stabilization was defined as readiness for discharge from the 
hospital: congestion was absent, and a stable, oral diuretic regimen established for at least 48 h. We collected blood 
samples at a relatively consistent time point, on the day of or before discharge. Finally, the small study population 
and the limited number of primary endpoints prevented a detailed and thorough investigation of whether the 
frequency of CD4+CD57+ T cells might serve as a prognostic factor in patients with acute HF. However, despite 
these limitations, our findings remain important, because we provided the first evidence to support a possible role 
of CD4+CD57+ senescent T cells in patients with acute HF.
Data Availability
The datasets used and/or analyzed during the current study available from the corresponding author on reason-
able request.
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